Начало・Списък с акции・DexCom Inc

DexCom Inc

Затворен

СекторЗдравеопазване

86.95 -0.29

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

85.87

Максимум

87.73

Ключови измерители
By Trading Economics
Приходи	50M 249M
Продажби	117M 1.3B
P/E Средно за сектора	34.51 68.51
EPS	0.7
Марж на печалбата	19.039
Служители	11,000
EBITDA	52M 389M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+3.68% upside

Дивиденти
By Acuity
Следващи печалби	29.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	4.6B 33B
Предишно отваряне	87.24
Предишно затваряне	86.95

Настроения в новините

By Acuity

21%

79%

64 / 340 Класиране в Healthcare

DexCom Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.08.2026 г., 19:56 ч. UTC

Dexcom Inc. shares are lower today, pulling back after reaching a session high. The broader market benefits from a significant decline in crude oil prices.

3.08.2026 г., 20:02 ч. UTC

News

Social Media

Dexcom Inc. shares are higher following strong Q2 results and raised revenue guidance to $5.22 billion. Canaccord increased its price target to $90.

31.07.2026 г., 20:04 ч. UTC

News

Social Media

Dexcom Inc. shares are higher following analyst upgrades and strong earnings, with second-quarter revenue of $1.31 billion exceeding expectations and guidance raised to $5.22 billion.

30.07.2026 г., 23:51 ч. UTC

News

Social Media

Dexcom reported second-quarter revenue of $1.308 billion and adjusted EPS of $0.70, raising its fiscal year 2026 revenue guidance, with shares trading higher in after-market hours.

29.07.2026 г., 23:41 ч. UTC

Dexcom Inc is trading higher in after-market hours, supported by overall market strength. The asset remains above its 20-day moving average.

28.07.2026 г., 20:06 ч. UTC

News

Dexcom shares rise after UBS initiated coverage with a Buy rating. The stock is advancing since Monday's close of $73.37 amid positive sentiment in the Health Care Equipment sector.

27.07.2026 г., 19:06 ч. UTC

News

Dexcom Inc. gains Health Canada approval for its Dexcom G7 continuous glucose monitoring system, boosting marketability and user adoption amid positive analyst sentiment.

24.07.2026 г., 15:22 ч. UTC

Dexcom Inc's shares are higher today, driven by gains in the Health Care Equipment sub-sector. No specific company news was identified for the movement.

22.07.2026 г., 20:01 ч. UTC

Dexcom Inc. shares are lower today, continuing a decline since Tuesday. Earlier, the stock briefly rose before pulling back.

21.07.2026 г., 19:26 ч. UTC

Dexcom Inc is trading lower, continuing a trend of three consecutive declines. The stock reached a session low earlier today before a slight recovery.

20.07.2026 г., 19:22 ч. UTC

Dexcom Inc shares are lower amid broader market declines and rising Treasury yields. The stock remains near the upper end of its one-month trading range.

Сравнение с други в отрасъла

Ценова промяна

DexCom Inc Прогноза

Ценова цел

By TipRanks

3.68% нагоре

12-месечна прогноза

Среден 90.52 USD 3.68%

Висок 112 USD

Нисък 64 USD

Според 23 анализатори от Wall Street, предложили 12-месечна ценова цел за DexCom Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

23 ratings

Купи

Задържане

Продай

Според 23 анализатори, дали борсови рейтинги на DexCom Inc през последните 3 месеца.

Настроение

By Acuity

64 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.